Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)1.66
  • Today's Change0.304 / 22.42%
  • Shares traded278.14k
  • 1 Year change-10.08%
  • Beta2.2403
Data delayed at least 15 minutes, as of Jul 14 2025 16:39 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

  • Revenue in EUR (TTM)46.84m
  • Net income in EUR-51.79m
  • Incorporated2000
  • Employees224.00
  • Location
    Cellectis SA8, rue de la Croix JarryPARIS 75013FranceFRA
  • Phone+33 181691600
  • Fax+33 181691606
  • Websitehttps://www.cellectis.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Adocia SA9.32m-9.32m68.73m77.00------7.37-0.6483-0.64830.6294-0.19770.3586--2.14121,039.00-35.87-47.62-164.77-104.50-----100.01-331.171.07-8.901.35--333.4934.1855.95---35.29--
Maat Pharma SA3.22m-28.90m74.94m60.00--6.29--23.30-2.21-2.210.24620.73950.0799.843.8353,600.00-70.99-41.51-104.45-51.8761.13---898.79-976.991.89-32.750.6069--44.34---46.59--42.53--
Eurofins-Cerep SA40.46m7.15m88.77m207.0012.411.249.282.191,418.431,418.438,027.2414,234.140.49551.614.75195,445.808.7613.1210.2315.9085.6780.0217.6820.226.53--0.0046---8.205.46-6.3410.36----
Sensorion SA0.00-25.97m93.81m63.00--1.30-----0.0923-0.09230.000.24010.00----0.00-38.26-34.53-46.44-43.50------------0.0285-------17.72--98.90--
Cellectis SA46.84m-51.79m97.85m224.00--0.987--2.09-0.5555-0.55550.49121.380.1524--4.58209,095.80-16.59-21.50-29.99-29.24---32.79-108.88-220.86---7.060.442--435.3716.4466.41---21.58--
Transgene SA6.08m-33.97m104.33m165.00--6.82--17.16-0.1633-0.16330.05230.11520.1392--6.1936,854.55-77.74-33.32-107.22-40.55-----558.64-251.37----0.4023---20.34-14.48-52.15--12.68--
Ose Immunotherapeutics SA83.44m37.45m116.15m64.003.711.742.851.391.371.373.552.910.81--32.591,303,672.0036.35-7.6644.85-9.27----44.88-26.10--14.190.4196--3,646.5226.31262.78---25.52--
Innate Pharma SA12.62m-49.47m138.46m168.00--14.25--10.97-0.61-0.610.15560.10540.0882--0.4171---34.57-13.29-46.32-17.3452.73---391.94-88.46----0.9001---75.68-28.80-553.51---64.08--
Data as of Jul 14 2025. Currency figures normalised to Cellectis SA's reporting currency: Euro EUR

Institutional shareholders

3.84%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 30 Nov 20231.35m1.87%
CDC Croissance SAas of 15 Feb 20251.04m1.44%
OFI Invest Asset Management SAas of 28 May 2025150.00k0.21%
Montpensier Arbevelas of 30 Dec 2022126.34k0.18%
Saint Olive Gestion SNCas of 29 Dec 202385.00k0.12%
Perinvest (UK) Ltd.as of 29 Sep 202310.29k0.01%
Mercer Global Investments Europe Ltd.as of 31 Dec 20249.40k0.01%
Sunny Asset Management SAas of 28 May 20250.000.00%
Capital Research & Management Co. (World Investors)as of 31 Mar 20250.000.00%
RAM Active Investments SAas of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 30 Jun 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.